Study #2024-0385
SWOG: Randomized phase III study of Mosunetuzumab vs. Rituximab for low tumor burden follicular lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Rituximab, Rituximab and Hyaluronidase Human, Mosunetuzumab
Description
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Study phase:
Phase III
Physician name:
Paolo Strati
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-833-767-1887
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.